Jefferies analyst Raj Denhoy noted that results from the "much-anticipated" ISCHEMIA trial were presented on Saturday and while he believes the findings will be debated for some time, he thinks there is unlikely to be much change in clinical practice because of ISCHEMIA and he sees little impact to Boston Scientific and others from the trial given that there was no difference shown in clinical events/outcomes between intervention and optimal medical management with drugs. His analysis points to a $13M potential impact on Boston Scientific sales, or about 0.1% of the $12.1B in revenue he forecasts for 2020, Denhoy noted. The analyst has a Buy rating and $49 price target on Boston Scientific shares.